Literature DB >> 16462763

Identification of vitamin D receptor as a target of p63.

R Kommagani1, T M Caserta, M P Kadakia.   

Abstract

p63, a p53 homolog has been shown to play a role in development and cancer. p63 is essential for both commitment of ectoderm to stratified epithelia and for the proliferative potential of epithelial stem cells. p63 knockout mice are born with severe development defects and lack organs of epithelial origin. In addition, p63 has also been shown to play a role in cancer development through the differential regulation of genes with tumor suppressor function and genes involved in metastasis. In order to understand the role of p63 in cancer and development, genes that are specifically regulated by p63 but not p53 were identified. In this study, we provide evidence that p63gamma specifically upregulates vitamin D Receptor (VDR). In contrast, p53 does not appear to be involved in upregulation of VDR expression. Additionally, we demonstrate that a naturally occurring p63 missense mutant, p63gamma (R279H) and p14(ARF), both act in a dominant negative manner to inhibit p63gamma-mediated upregulation of VDR. Furthermore, using chromatin immunoprecipitation assays, we demonstrated that p63 directly binds to the VDR promoter in vivo. Our findings clearly demonstrate that VDR is a direct target of p63 and suggests that p63 may play a role in cancer and differentiation through modulation of the VDR pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462763     DOI: 10.1038/sj.onc.1209412

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

Review 1.  Vitamin D receptor and RXR in the post-genomic era.

Authors:  Mark D Long; Lara E Sucheston-Campbell; Moray J Campbell
Journal:  J Cell Physiol       Date:  2015-04       Impact factor: 6.384

2.  Modulation of the vitamin D3 response by cancer-associated mutant p53.

Authors:  Perry Stambolsky; Yuval Tabach; Giulia Fontemaggi; Lilach Weisz; Revital Maor-Aloni; Zehava Siegfried; Zahava Sigfried; Idit Shiff; Ira Kogan; Moshe Shay; Eyal Kalo; Giovanni Blandino; Itamar Simon; Moshe Oren; Varda Rotter
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

3.  Differential regulation of vitamin D receptor (VDR) by the p53 Family: p73-dependent induction of VDR upon DNA damage.

Authors:  Ramakrishna Kommagani; Vandana Payal; Madhavi P Kadakia
Journal:  J Biol Chem       Date:  2007-08-23       Impact factor: 5.157

4.  Vitamin D metabolism and effects on pluripotency genes and cell differentiation in testicular germ cell tumors in vitro and in vivo.

Authors:  Martin Blomberg Jensen; Anne Jørgensen; John Erik Nielsen; Andreas Steinmeyer; Henrik Leffers; Anders Juul; Ewa Rajpert-De Meyts
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

5.  Regulation of VDR by deltaNp63alpha is associated with inhibition of cell invasion.

Authors:  Ramakrishna Kommagani; Mary K Leonard; Stefanie Lewis; Rose-Anne Romano; Satrajit Sinha; Madhavi P Kadakia
Journal:  J Cell Sci       Date:  2009-07-21       Impact factor: 5.285

6.  Pan-cancer analyses of the nuclear receptor superfamily.

Authors:  Mark D Long; Moray J Campbell
Journal:  Nucl Receptor Res       Date:  2015-12-15

7.  Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway.

Authors:  Carly M Kemmis; JoEllen Welsh
Journal:  J Cell Biochem       Date:  2008-11-01       Impact factor: 4.429

Review 8.  p63-related signaling at a glance.

Authors:  Matthew L Fisher; Seamus Balinth; Alea A Mills
Journal:  J Cell Sci       Date:  2020-09-11       Impact factor: 5.285

9.  Differential effects of p63 mutants on transactivation of p53 and/or p63 responsive genes.

Authors:  Shama K Khokhar; Ramakrishna Kommagani; Madhavi P Kadakia
Journal:  Cell Res       Date:  2008-10       Impact factor: 25.617

10.  p73 is essential for vitamin D-mediated osteoblastic differentiation.

Authors:  R Kommagani; A Whitlatch; M K Leonard; M P Kadakia
Journal:  Cell Death Differ       Date:  2009-09-25       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.